AbCellera Biologics Inc
Company Profile
Business description
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Contact
150 W 4th Avenue
VancouverBCV5Y 1G6
CANT: +1 604 559-9005
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
562
Stocks News & Analysis
stocks
Are ASX REITs the better way to own property?
stocks
Cheap Dividend Aristocrat has Fair Value raised after earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,279.00 | 3.00 | -0.03% |
| CAC 40 | 8,579.60 | 57.19 | -0.66% |
| DAX 40 | 26,338.61 | 101.70 | -0.38% |
| Dow JONES (US) | 53,541.83 | 190.58 | -0.35% |
| FTSE 100 | 10,720.30 | 29.81 | -0.28% |
| HKSE | 25,453.23 | 336.38 | 1.34% |
| NASDAQ | 26,719.34 | 9.82 | -0.04% |
| Nikkei 225 | 69,220.25 | 506.45 | 0.74% |
| NZX 50 Index | 13,721.98 | 132.40 | -0.96% |
| S&P 500 | 7,770.50 | 15.26 | -0.20% |
| S&P/ASX 200 | 9,073.20 | 6.10 | -0.07% |
| SSE Composite Index | 3,982.65 | 55.48 | 1.41% |